The overall objective of this revised competitive renewal application is to determine the molecular mechanisms responsible for Hyperhomocysteinemia (HHcy)-induced endothelial cell (EC) growth inhibition. We provided initial evidence demonstrating that pathophysiologically relevant concentrations of homocysteine (Hcy) inhibit EC growth, but not that of other cell types, through a hypomethylation related mechanism. In the previous grant period, we discovered that Hcy inhibits cyclin A transcription, DNA methyltransferase 1 (DNMT1) activity and DNA methylation in cyclin A promoter, and that adenovirus-transduced expression of cyclin A and DNMT1 genes rescued EC growth from the inhibitory effect of Hcy. Our in vivo studies indicate that HHcy impairs endothelial function and eNOS activity via PKC activation, and that HHcy impaired reendothelialization and increased neointimal formation in mice. Our basic hypothesis is that that Hcy impairs reendothelialization via inhibition of EC proliferation, and contribute, to the increased atherosclerosis in HHcy. This project will study this hypothesis utilizing three linked specific aims. First, in Aim 1, we will explore the regulatory mechanisms of Hcy-induced cyclin D2/D3 suppression in EC. Second, in Aim 2, we will Determine biochemical basis of Hcy-hypomethylation and growth inhibition in EC. Finally, in Aim 3, we will examine the effect of EC therapy in post-injury reendothelialization and neointima formation in HHcy mice. We believe that completion of the specific aims should provide valuable new information to establish the links between HHcy and atherosclerosis, and lead to therapeutic advantage. PUBLIC HUMAN

Public Health Relevance

It has been suggested that HHcy accounts for the higher prevalence of CVD in renal disease, diabetes, ageing and in postmenopausal women that is not explained by traditional risk factors. However, the underlying mechanism is largely unknown and the role of homocysteine (Hcy)-induced endothelial growth inhibition in CVD is unclear. We have previously demonstrated that Hcy exerts highly selective inhibitory effect on cyclin A transcription and EC growth through a hypomethylation related mechanism, which blocks cell cycle progression and endothelium regeneration. Since endothelial injury is an early event in vascular disease, and since endothelial regeneration determines the onset of atherosclerosis, we hypothesize that Hcy promotes atherosclerosis by impairing reendothelialization via inhibition of EC proliferation. In this proposal, we propose to investigate the role and mechanisms of HHcy in altering EC metabolism and EC biology, with the goal of identifying the underlying mechanisms, using in vitro and in vivo approaches.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL067033-08
Application #
7810735
Study Section
Vascular Cell and Molecular Biology Study Section (VCMB)
Program Officer
Ershow, Abby
Project Start
2001-04-01
Project End
2012-03-31
Budget Start
2010-04-01
Budget End
2011-03-31
Support Year
8
Fiscal Year
2010
Total Cost
$375,000
Indirect Cost
Name
Temple University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
057123192
City
Philadelphia
State
PA
Country
United States
Zip Code
19122
Xu, Yanjie; Xia, Jixiang; Liu, Suxuan et al. (2017) Endocytosis and membrane receptor internalization: implication of F-BAR protein Carom. Front Biosci (Landmark Ed) 22:1439-1457
Xi, Hang; Zhang, Yuling; Xu, Yanjie et al. (2016) Caspase-1 Inflammasome Activation Mediates Homocysteine-Induced Pyrop-Apoptosis in Endothelial Cells. Circ Res 118:1525-39
Yang, Jiyeon; Fang, Pu; Yu, Daohai et al. (2016) Chronic Kidney Disease Induces Inflammatory CD40+ Monocyte Differentiation via Homocysteine Elevation and DNA Hypomethylation. Circ Res 119:1226-1241
Liu, Suxuan; Xiong, Xinyu; Thomas, Sam Varghese et al. (2016) Analysis for Carom complex, signaling and function by database mining. Front Biosci (Landmark Ed) 21:856-72
Nelson, Jun; Wu, Yi; Jiang, Xiaohua et al. (2015) Hyperhomocysteinemia suppresses bone marrow CD34+/VEGF receptor 2+ cells and inhibits progenitor cell mobilization and homing to injured vasculature-a role of ?1-integrin in progenitor cell migration and adhesion. FASEB J 29:3085-99
Cheng, Zhongjian; Jiang, Xiaohua; Pansuria, Meghana et al. (2015) Hyperhomocysteinemia and hyperglycemia induce and potentiate endothelial dysfunction via ?-calpain activation. Diabetes 64:947-59
Liu, Suxuan; Xiong, Xinyu; Zhao, Xianxian et al. (2015) F-BAR family proteins, emerging regulators for cell membrane dynamic changes-from structure to human diseases. J Hematol Oncol 8:47
Tan, Hongmei; Shi, Chengwei; Jiang, Xiaohua et al. (2014) Hyperhomocysteinemia promotes vascular remodeling in vein graph in mice. Front Biosci (Landmark Ed) 19:958-66
Huang, Xiao; Gong, Ren; Li, Xinyuan et al. (2013) Identification of novel pretranslational regulatory mechanisms for NF-?B activation. J Biol Chem 288:15628-40
Yin, Ying; Pastrana, Jahaira Lopez; Li, Xinyuan et al. (2013) Inflammasomes: sensors of metabolic stresses for vascular inflammation. Front Biosci (Landmark Ed) 18:638-49

Showing the most recent 10 out of 37 publications